Sodium Chloride 0.9% ( DrugBank: Sodium chloride, Chloride )


2 diseases
IDDisease name (Link within this page)Number of trials
14Chronic inflammatory demyelinating polyneuropathy3
227Osler disease1

14. Chronic inflammatory demyelinating polyneuropathy


Clinical trials : 175 Drugs : 161 - (DrugBank : 41) / Drug target genes : 13 - Drug target pathways : 24
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2017-002511-34-GB
(EUCTR)
01/04/201908/11/2019Initial treatment of chronic inflammatory demyelinating polyneuropathy (CIDP) - combined immunoglobulin and steroid treatment versus immunoglobulin treatment alone.Intravenous immunoglobulin and intravenous methylprednisolone as optimal induction treatment in CIDP - OPTIC Trial Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
MedDRA version: 21.1;Level: PT;Classification code 10057645;Term: Chronic inflammatory demyelinating polyradiculoneuropathy;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Trade Name: methylprednisolone
Product Name: methylprednisolone
Trade Name: sodium chloride 0.9%
Product Name: sodium chloride 0.9%
Academic Medical Centre, Amsterdam, NLNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
96Phase 3Netherlands;United Kingdom
2EUCTR2017-002511-34-NL
(EUCTR)
26/09/201817/04/2018Intravenous immunoglobulin and intravenous methylprednisolone as optimal induction treatment in CIDP(OPTIC trial)Intravenous immunoglobulin and intravenous methylprednisolone as optimal induction treatment in CIDP(OPTIC trial) - OPTIC trial Chronic inflammatory demyelinating polyneuropathy (CIDP);Therapeutic area: Diseases [C] - Nervous System Diseases [C10]Trade Name: Methylprednisolone (Solu-Medrol)
Product Name: Methylprednisolon (Solu-Medrol)
Trade Name: Sodium Chloride 0.9%
Product Name: Sodium Chloride 0.9%
Product Code: RVG 56083
Academisch Medisch CentrumNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
96Phase 3Netherlands
3EUCTR2013-005363-52-NL
(EUCTR)
10/09/201427/03/2014Intravenous immunoglobulin overtreatment in CIDPIntravenous immunoglobulin overtreatment in chronic inflammatory demyelinating polyneuropathy (CIDP) Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP);Therapeutic area: Diseases [C] - Nervous System Diseases [C10]Trade Name: Sodium Chloride 0.9%
Product Name: Sodium Chloride 0.9%
Product Code: RVG 51680
Department of Neurology, Academic Medical CenterNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
Netherlands

227. Osler disease


Clinical trials : 56 Drugs : 72 - (DrugBank : 21) / Drug target genes : 23 - Drug target pathways : 136
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03227263
(ClinicalTrials.gov)
September 28, 201721/7/2017BABH Study: Efficacy and Safety of Bevacizumab on Severe Bleedings Associated With Hemorrhagic Hereditary Telangiectasia (HHT).BABH Study: Efficacy and Safety of Bevacizumab on Severe Bleedings Associated With Hemorrhagic Hereditary Telangiectasia (HHT). A National, Multicenter Phase III StudyRendu Osler Disease;Telangiectasia, Hereditary HemorrhagicDrug: Bevacizumab;Drug: sodium chloride 0.9%Hospices Civils de LyonNULLCompleted18 YearsN/AAll24Phase 3France